Clinical Trial Detail

NCT ID NCT02422589
Title A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
Recruitment Completed
Gender
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

non-small cell lung carcinoma

Therapies

Warfarin

Midazolam

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST